Staff Profile

• Co-Director, Leukaemia Research Cytogenetics Group
• Genetics lead, NCRI Childhood Cancer and Leukaemia Group (CCLG) Leukaemia Subgroup
• Genetics lead, NCRI Haematological Malignancy Study Group - Adult ALL Working Party
• Lead, Childhood Leukaemia sub-domain, Genomics England Haematology Malignancy Clinical Interpretation Partnership
• Genetics co-ordinator for the following clinical trials – UKALL2011, UKALL14, UKALL60 , IntReALL2010

Area of expertise

• Cancer genetics

• Bloodwise Childhood Leukaemia Cell Bank Steering Committee
• NHS Southampton & SW Hampshire Local Research Ethics Committee (2003 - 2005)

• International Membership of the American Society of Hematology
• International BFM Study Group

• EU Innovative Medicines Initiative (116026) Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology (HARMONY) 2016-2021. Lead: Jesús M Hernández; Participants leading on Childhood Leukaemia: Anthony Moorman, Dirk Reinhardt, Franco Locatelli. (Total Euro 20m)
• Cancer Research UK 2016-2021. Personalising therapy for adults with acute lymphoblastic leukaemia. Anthony Moorman &  Adele Fielding (co-PIs), £2m
• Bloodwise 2016-2021. Leukaemia Research Cytogenetics Group Specialist Programme. Anthony Moorman & Christine Harrison (co-PIs) £3m
• Bloodwise Gordon Pillar Studentship 2016-2019 IKZF1 lesions in adult acute lymphoblastic lymphoma - the chicken or the egg? Adele Fielding (PI), Elli Papaemmanuil, Anthony Moorman. £148,596.00
• Newcastle Healthcare Charity  2015-2016. Clinical evaluation of genetic biomarkers in childhood acute lymphoblastic leukaemia. Anthony Moorman & Christine Harrison. £19,623

Google Scholar: Click here.

The central philosophy of my research is based on the premise that the genetic heterogeneity of cancer is the key to furthering our understanding of the disease and to improving patient management and outcome. During my research career, I have focused on integrating high quality genetic information into the analysis of clinical trials and aetiological studies of acute leukaemia. Over the past 20 years, I have been involved in the development of an innovative research network which interfaces the Leukaemia Research Cytogenetics Group (LRCG) with clinicians, trial coordinators and geneticists. The establishment, maintenance and development of this innovative framework have enabled the curation and genetic annotation of samples from clinical trial patients diagnosed with acute leukaemia. Currently, the LRCG holds genetic, demographic and clinical data on more than 27,000 patients treated on over 15 National Cancer Research Institute (NCRI) clinical trials. This research infrastructure is unique because it encompasses two major haematological cancers (acute lymphoblastic and myeloid leukaemia) and is not restricted by the age of the patient.

We conduct comprehensive, pertinent and meticulous assessments of the clinical relevance of genetic markers within the context of national and international clinical trials. The objective is to provide clinicians with pertinent and reliable evidence to enable them to decide on the most effective course of treatment for their patients. The ultimate test of our work – at the interface between evidence-based genetic research and clinical practice - is its translational impact. Two major achievements with a direct impact on patient outcome have been: (1) the identification of a novel marker of poor outcome in childhood ALL [Blood, 2007, 109:2327]. This led directly to a protocol modification in the subsequent paediatric trial, so patients with this abnormality were transferred to the more intensive treatment arm. This change in treatment has reduced the risk of relapse in this subgroup of patients from >75% to <10%; (2) the comprehensive assessment of the clinical relevance of cytogenetics in adult ALL [Blood, 2007, 109:3189; Blood, 2009, 113:4489; Blood, 2009, 114:5136]. The results of this study led directly to patients with one of three chromosomal abnormalities being classified as high risk and treated differentially in the new adult ALL trial, UKALL14. The results of this study have also been used by other clinical groups to risk-stratify patients.

BSc in Biomedical Studies (Project Supervision)

MRes in Medical Sciences (Project Supervision)

MSc in Medical Sciences (Project Supervision & Medical Research in 21st Century Module)

PhD supervision

Research Student Development Programme ("Getting that first post-doc position" & "What makes a good poster?")

• Articles

  • Ryan SL, Peden JF, Kingsbury Z, Schwab CJ, James T, Polonen P, Mijuskovic M, Becq J, Yim R, Cranston RE, Hedges DJ, Roberts KG, Mullighan CG, Vora A, Russell LJ, Bain R, Moorman AV, Bentley DR, Harrison CJ, Ross MT. Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia. Leukemia 2023, 37, 518-528.
  • Ostergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, Den Boer ML, Kuiper RP, Moorman AV, Boer JM, Van Leeuwen FN. The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia. HemaSphere 2023, 7(5), e875.
  • Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell International 2023, 23, 202.
  • Enshaei A, Martinez Elicegui J, Anguiano E, Gibson J, Lawal S, Ampatzidou M, Doubek M, Fielding AK, La Sala E, Middleton E, Rijneveld AW, Turki AT, Zimmermann M, Vora A, Moorman AV. Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform. Leukemia 2023, 37, 2493–2496.
  • Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns MA, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui C-H, Stary J, Cario G, Bodmer N, Moorman AV, Buldini B, Vora A, Valsecchi MG. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. Journal of Clinical Oncology 2023, 41(32), 5025-5034.
  • Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, Moorman AV, Harrison CJ. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia 2023, 37, 529-538.
  • Elitzur S, Vora A, Burkhardt B, Inaba H, Attarbaschi A, Baruchel A, Escherich G, Gibson B, Liu H-C, Loh M, Moorman AV, Moricke A, Pieters R, Uyttebroeck A, Baird S, Bartram J, Barzilai-Birenboim S, Batra S, Ben-Harosh M, Bertrand Y, Buitenkamp T, Caldwell K, Drut R, Geerlinks AV, Gilad G, Grainger J, Haouy S, Heaney N, Huang M, Ingham D, Krenova Z, Kuhlen M, Lehrnbecher T, Manabe A, Niggli F, Paris C, Revel-Vilk S, Rohrlich P, Sinno MG, Szczepanski T, Tamesberger M, Warrier R, Wolfl M, Nirel R, Izraeli S, Borkhardt A, Schmiegelow K. EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. Blood 2023, 141(7), 743-755.
  • Sinclair PB, Cranston RE, Raninga P, Cheng J, Hanna R, Hawking Z, Hair S, Ryan SL, Enshaei A, Nakjang S, Rand V, Blair HJ, Moorman AV, Heidenreich O, Harrison CJ. Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia 2023, 37, 636–649.
  • Ohki K, Butler ER, Kiyokawa N, Hirabayashi S, Bergmann AK, Moricke A, Boer JM, Cave H, Cazzaniga G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan CG, Loh ML, Noren-Nystrom U, Shih L-Y, Zaliova M, Pui C-H, Haas OA, Harrison CJ, Moorman AV, Manabe A. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group. Leukemia 2023, 37, 212-216.
  • Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. Journal of Clinical Oncology 2022, 40(36), 4228-4239.
  • Taj MM, Moorman AV, Hamadeh L, Petit A, Asnafi V, Alby-Laurent F, Vora A, Mansour MR, Gale R, Chevret S, Moppett J, Baruchel A, Macintyre E. Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. Leukemia 2022, 36(1), 263-266.
  • Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 2022, 36, 625-636.
  • Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung K, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, Cazzaniga G, Gohring G, de Groot-Kruseman H, Haferlach C, Lo Nigro L, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, van der Velden V, Rand V, Hunger SP, Harrison CJ, Bacon C, van Delft F, Loh M, Moppett J, Vormoor J, Walker B, Moorman AV, Russell L. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematologica 2023, 108(3), 717-731.
  • Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, Moorman AV, Morley N, Okasha D, Patel B, Patrick P, Potter MN, Rowntree CJ, Kirkwood AA, Fielding AK. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. The Lancet Haematology 2022, 9(4), e276-e288.
  • Pal D, Blair H, Parker J, Hockney S, Beckett M, Singh M, Tirtakusuma R, Nelson R, McNeill H, Angel SH, Wilson A, Nizami S, Nakjang S, Zhou P, Schwab C, Sinclair P, Russell LJ, Coxhead J, Halsey C, Allan JM, Harrison CJ, Moorman AV, Heidenreich O, Vormoor J. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine 2022, 3(8), 100717.
  • Ambayya A, Moorman AV, Sathar J, Eswaran J, Sulong S, Hassan R. Genetic profiles and risk stratification in adult de novo acute myeloid leukaemia in relation to age, gender, and ethnicity: A study from Malaysia. International Journal of Molecular Sciences 2022, 23(1), 258.
  • Schwab CJ, Murdy D, Butler E, Enshaei A, Winterman E, Cranston RE, Ryan S, Barretta E, Hawking Z, Murray J, Antony G, Vora A, Moorman AV, Harrison CJ. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. British Journal of Haematology 2022, 196(3), 753-763.
  • Creasey T, Barretta E, Ryan SL, Butler E, Kirkwood AA, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Morley N, Marks DI, Fielding AK, Moorman AV. Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. Haematologica 2022, 107(9), 2051-2063.
  • Antic Z, Yu J, Bornhauser BC, Lelieveld SH, van der Ham CG, van Reijmersdal SV, Morgado L, Elitzur S, Bourquin J-P, Cazzaniga G, Eckert C, Camos M, Sutton R, Cave H, Moorman AV, Sonneveld E, Geurts van Kessel A, van Leeuwen FN, Hoogerbrugge PM, Waanders E, Kuiper RP. Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. Pediatric Blood and Cancer 2022, 69(1), e29361.
  • Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, Moorman AV, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. The Lancet Haematology 2022, 9(4), e262-e275.
  • Sidhu J, Masurekar AN, Gogoi MP, Fong C, Ioannou T, Lodhi T, Parker C, Liu J, Kirkwood AA, Moorman AV, Das K, Goulden NJ, Vora A, Saha V, Krishnan S. Activity and toxicity of intramuscular 1000 iu/m² polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials. British Journal of Haematology 2022, 198(1), 142-150.
  • Creasey T, Enshaei A, Nebral K, Schwab C, Watts K, Cuthbert G, Vora A, Moppett J, Harrison CJ, Fielding AD, Haas OA, Moorman AV. Single nucleotide polymorphism (SNP) array-based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2021, 60(9), 604-615.
  • Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, Revesz T, Hoogerbrugge P, Hancock J, Sutton R, Henze G, Chen-Santel C, Attarbaschi A, Bourquin J-P, Sramkova L, Zimmermann M, Krishnan S, von Stackelberg A, Saha V. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. European Journal of Cancer 2021, 151, 175-189.
  • Naomi M, Boer JM, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur-Stadt U, Schmiegelow K, Moorman AV, Zwaan CM, den Boer M. Minimal Residual Disease, Long-Term Outcome, and IKZF1 Deletions in Down Syndrome Acute Lymphoblastic Leukemia in a Matched Cohort Study. SSRN 2021. Submitted.
  • Mitchell RJ, Kirkwood AA, Barretta E, Clifton-Hadley L, Lawrie E, Lee S, Leongamornlert D, Marks DI, McMillan AK, Menne TF, Papaemmanuil E, Patel B, Patrick P, Rowntree CJ, Zareian N, Alapi KZ, Moorman AV, Fielding AK. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Advances 2021, 5(17), 3322-3332.
  • Lin W-Y, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann W-K, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Stolzel F, Onel K, Allan JM. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications 2021, 12(1), 6233.
  • Toksvang LN, Grell K, Nielsen SN, Nersting J, Murdy D, Moorman AV, Vora A, Schmiegelow K. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia. Leukemia 2021, 36, 555-557.
  • Enshaei A, Vora A, Harrison CJ, Moppett J, Moorman AV. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. The Lancet Haematology 2021, 8(11), e828-e839.
  • Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Moricke A, Boer JM, Cave H, Cazzaniga G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan C, Loh ML, Noren-Nystrom U, Pastorczak A, Shih L-Y, Zaliova M, Pui C-H, Haas OA, Harrison CJ, Moorman AV, Manabe A. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia 2021, 35, 3272–3277.
  • Stanulla M, Cave H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?. Blood 2020, 135(4), 252-260.
  • Winer P, Muskens IS, Walsh KM, Vora A, Moorman AV, Wiemels JL, Roberts I, Roy A, De Smith AJ. Germline variants in predisposition genes in children with down syndrome and acute lymphoblastic leukemia. Blood Advances 2020, 4(4), 672-675.
  • Bashton M, Hollis R, Ryan S, Schwab CJ, Moppett J, Harrison CJ, Moorman AV, Enshaei A. Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. Scientific Reports 2020, 10, 45.
  • Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion. British Journal of Haematology 2020, 191(5), 844-851.
  • Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman AV. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood 2020, 135(17), 1438-1446.
  • Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, Moorman AV. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances 2019, 3(2), 148-157.
  • Sinclair PB, Ryan S, Bashton M, Hollern S, Hanna R, Case M, Schwalbe EC, Schwab CJ, Cranston RE, Young BD, Irving JAE, Vora AJ, Moorman AV, Harrison CJ. SH2B3 inactivation through CN-LOH-12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. Leukemia 2019, 33, 1881-1894.
  • Parker C, Krishnan S, Hamadeh L, Irving JAE, Kuiper RP, Revesz T, Hoogerbrugge P, Hancock J, Sutton R, Moorman AV, Saha V. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. The Lancet Haematology 2019, 6(4), e204-e216.
  • Vijayakrishnan J, Qian M, Studd JB, Yang W, Kinnersley B, Law PJ, Broderick P, Raetz EA, Allan J, Pui C-H, Vora A, Evans WE, Moorman A, Yeoh A, Yang W, Li C, Bartram CR, Mullighan CG, Zimmerman M, Hunger SP, Schrappe M, Relling MV, Stanulla M, Loh ML, Houlston RS, Yang JJ. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications 2019, 10(1), 5348.
  • Bartram J, O'connor D, Enshaei A, Moorman A. Combining Genotype Profiling with MRD for More Accurate Prognostication in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(Supplement 1), S63-S65.
  • Warrender JD, Moorman AV, Lord P. A fully computational and reasonable representation for karyotypes. Bioinformatics 2019, 35(24), 5264-5270.
  • Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt S-M, Vermeersch P, de Keersmaecker K. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL. Leukemia 2018, 33(2), 319-322.
  • Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang Y-L, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui C-H, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018, 562(7727), 373-379.
  • Sellar RS, Rowntree C, Vora AJ, Furness CL, Goulden N, Mitchell C, Moorman AV, Hough R. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: Results from UKALL2003. British Journal of Haematology 2018, 181(4), 515-522.
  • Potter C, Moorman AV, Relton CL, Ford D, Mathers JC, Strathdee G, McKay JA. Maternal red blood cell folate and infant vitamin B12 status influence methylation of genes associated with childhood acute lymphoblastic leukaemia. Molecular Nutrition & Food Research 2018, 62(22), 1800411C.
  • Smith L, Glaser AW, Kinsey SE, Greenwood DC, Chilton L, Moorman AV, Feltbower RG. Long-term survival after childhood acute lymphoblastic leukaemia: Population-based trends in cure and relapse by clinical characteristics. British Journal of Haematology 2018, 182(6), 851-858.
  • Hrusak O, De Haas V, Stancikova J, Vakrmanova B, Janotova I, Mejstrikova E, Capek V, Trka J, Zaliova M, Luks A, Bleckmann K, Moricke A, Irving J, Konatkowska B, Alexander TB, Inaba H, Schmiegelow K, Stokley S, Zemanova Z, Moorman AV, Rossi JG, Felice MS, Dalla-Pozza L, Morales J, Dworzak M, Buldini B, Basso G, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, Luria D, Feuerstein T, Kolenova A, Svec P, Kreminska O, Rabin KR, Polychronopoulou S, Da Costa E, Marquart HV, Kattamis A, Ratei R, Reinhardt D, Choi JK, Schrappe M, Stary J. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood 2018, 132(3), 264-276.
  • Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2018, 9(1), 1340.
  • Sinclair PB, Blair HH, Ryan SL, Buechler L, Cheng J, Clayton J, Hanna R, Hollern S, Hawking Z, Bashton M, Schwab CJ, Jones L, Russell LJ, Marr H, Carey P, Halsey C, Heidenreich O, Moorman AV, Harrison CJ. Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Haematologica 2018, 103, 634-644.
  • O'Connor D, Moorman AV, Wade R, Hancock J, Tan RMR, Bartram J, Moppett J, Schwab C, Patrick K, Harrison CJ, Hough R, Goulden N, Vora A, Samarasinghe S. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology 2017, 35(6), 660-667.
  • Schwab CJ, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, Zaliova M, Sutton R, Ofverholm II, Ohki K, Yamashita Y, Groeneveld-Krentz S, Fronkova E, Bakkus M, Tchinda J, Conceicao-Barbosa T, Fazio G, Mlynarski W, Pastorczak A, Cazzaniga G, Pombo-de-Oliveira MS, Trka J, Kirschner-Schwabe R, Imamura T, Barbany G, Stanulla M, Attarbaschi A, Panzer-Grumayer R, Kuiper RP, den-Boer ML, Cave H, Moorman AV, Harrison CJ, Strehl S. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. Blood Advances 2017, 1, 1473-1477.
  • Enshaei A, OConnor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2017, 36(1), 34-43.
  • Chilton L, Harrison CJ, Ashworth I, Murdy D, Burnett AK, Grimwade D, Moorman AV, Hills RK. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 2017, 31(5), 1234–1237.
  • Vijayakrishnan J, Kumar R, Henrion MYR, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jockel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 2017, 31(3), 573-579.
  • Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ. The role of the RAS pathway in iAMP21-ALL. Leukemia 2016, 30, 1824-1831.
  • Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2016, 128(7), 911-922.
  • Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrozek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications 2016, 7, 13331.
  • Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Falkenburg JHF, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica 2016, 101(9), 1082-1093.
  • Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2016, 56(5), 363-372.
  • Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
  • Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nothen MM, Muhleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Scientific Reports 2015, 5, 15065.
  • Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, Lahortiga I, Elliott A, Chilton L, LaStarza R, Mecucci C, Vandenberghe P, Goulden N, Vora A, Moorman AV, Soulier J, Harrison CJ, Clappier E, Cools J. Targeted Sequencing Identifies Association Between IL7R-JAK Mutations And Epigenetic Modulators In T-Cell Acute Lymphoblastic Leukemia. Haematologica 2015, 100, 1301-1310.
  • Boer JM, vanderVeer A, Rizopoulos D, Fiocco M, Sonneveld E, deGroot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, Pombo-de-Oliveira MS, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, denBoer ML. Prognostic value of rare IKZF1 deletion in childhood b-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2015, 1-7.
  • Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, Bornhauser B, Gombert M, Kratsch C, Stutz AM, Sultan M, Tchinda J, Worth CL, Amstislavskiy V, Badarinarayan N, Baruchel A, Bartram T, Basso G, Canpolat C, Cario G, Cave H, Dakaj D, Delorenzi M, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas OA, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Holl JI, Hornhardt S, Husemann P, Kachroo P, Kratz CP, te Kronnie G, Marovca B, Niggli F, McHardy AC, Moorman AV, Panzer-Grumayer R, Petersen BS, Raeder B, Ralser M, Rosenstiel P, Schafer D, Schrappe M, Schreiber S, Schutte M, Stade B, Thiele R, von der Weid N, Vora A, Zaliova M, Zhang LH, Zichner T, Zimmermann M, Lehrach H, Borkhardt A, Bourquin JP, Franke A, Korbel JO, Stanulla M, Yaspo ML. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics 2015, 47(9), 1020-1029.
  • Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
  • Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014, 123(6), 843-850.
  • Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V. Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia - Prospective Open Cohort Analyses of the ALLR3 Trial. PLoS ONE 2014, 9(10), e108107.
  • Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, Jenkinson S, Hough R, Vora A. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. British Journal of Haematology 2014, 166(3), 421-424.
  • Patel B, Dey A, Castleton AZ, Schwab C, Samuel E, Sivakumaran J, Beaton B, Zareian N, Zhang CY, Rai L, Enver T, Moorman AV, Fielding AK. Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. Blood 2014, 124(1), 96-105.
  • Chilton L, Hills RK, Harrison CJ, Burnett AK, Grimwade D, Moorman AV. Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome. Leukemia 2014, 28(2), 321-328.
  • Chilton L, Buck G, Harrison CJ, Ketterling RP, Rowe JM, Tallman MS, Goldstone AH, Fielding AK, Moorman AV. High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome. Leukemia 2014, 28(7), 1511-1518.
  • Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P, Moorman AV, Dyer S, Borrow J, Griffiths M, Heerema NA, Carroll AJ, Talley P, Bown N, Telford N, Ross FM, Gaunt L, McNally RJ, Young BD, Sinclair P, Rand V, Teixeira MR, Joseph O, Robinson B, Maddison M, Dastugue N, Vandenberghe P, Haferlach C, Stephens PJ, Cheng J, Van-Loo P, Stratton MR, Campbell PJ, Harrison CJ. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014, 508(7494), 98-102.
  • Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncology 2014, 15(8), 809-818.
  • Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Recher C, Chilton L, Moorman AV, Burnett AK. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncology 2014, 15(9), 986-996.
  • Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Biondi A, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Morak M, Panzer-Grumayer R, Mondelaers V, Lammens T, Cave H, Stark B, Ganmore I, Moorman AV, Vora A, Hunger SP, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk JR, Whitlock JA, Zwaan CM. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 2014, 123(1), 70-77.
  • Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, Richardson S, Hancock J, Kinsey SE, Mitchell CD, Goulden N, Vora A, Harrison CJ. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014, 124(9), 1434-1444.
  • Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, Laczko KS, Fielding AK, Goldstone AH, Goulden N, Mitchell CD, Wade R, Vora A, Moorman AV, Harrison CJ. IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology 2014, 32(14), 1453-1462.
  • Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 2013, 98(6), 945-952.
  • Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison C, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated on UKALLXII/ECOG2993. Haematologica 2013, 98(6), 945-952.
  • Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell CD, Goulden N, Vora A, Harrison CJ. Risk-Directed Treatment Intensification Significantly Reduces the Risk of Relapse Among Children and Adolescents With Acute Lymphoblastic Leukemia and Intrachromosomal Amplification of Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 Trials. Journal of Clinical Oncology 2013, 31(27), 3389-3396.
  • Enshaei A, Schwab CJ, Konn ZJ, Mitchell CD, Kinsey SE, Wade R, Vora A, Harrison CJ, Moorman AV. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia 2013, 27(11), 2256-2259.
  • Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman AV, Linch DC, Gale RE. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 2013, 27(1), 41-47.
  • Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica 2013, 98(7), 1081-1088.
  • Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, Strehl S, Nebral K, Harbott J, Teigler-Schlegel A, Zimmerman M, Dastuge N, Baruchel A, Soulier J, Auclerc MF, Attarbaschi A, Mann G, Stark B, Cazzaniga G, Chilton L, Vandenberghe P, Forestier E, Haltrich I, Raimondi SC, Parihar M, Bourquin JP, Tchinda J, Haferlach C, Vora A, Hunger SP, Heerema NA, Haas OA. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2013, 1-7.
  • Al-Shehhi H, Konn ZJ, Schwab CJ, Erhorn A, Barber KE, Wright SL, Gabriel AS, Harrison CJ, Moorman AV. Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2013, 52(2), 202-213.
  • Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Potschger U, Harrison CJ, Stanulla M, Panzer-Grumayer R, Haas OA, Moorman AV, Assoc Italiana Ematologia Oncologi, Natl Canc Res Inst NCRI-Childrens. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology 2012, 158(6), 772-777.
  • Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. British Journal of Haematology 2012, 157(4), 463-471.
  • Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JPP, Beverloo HB, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Russell LJ, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, den Boer ML, Zwaan CM. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012, 26(10), 2204-2211.
  • O'Neill KA, Bunch KJ, Vincent TJ, Spector LG, Moorman AV, Murphy MFG. Immunophenotype and Cytogenetic Characteristics in the Relationship Between Birth Weight and Childhood Leukemia. Pediatric Blood & Cancer 2012, 58(1), 7-11.
  • Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G. Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity. Haematologica 2012, 97(3), 371-378.
  • Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Masic D, Patel B, Rowe JM, Tallman M, Goldstone AH, Fielding AK, Harrison CJ. IGH@ Translocations, CRLF2 Deregulation and Microdeletions in Adolescents and Adults with Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2012, 30(25), 3100-3108.
  • Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J, Jones L, Masic D, Minto L, Morrison H, Ryan S, Robinson H, Sinclair P, Moorman A, Strefford J, Harrison CJ. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2011, 117(25), 6848-6855.
  • Anderson K, Lutz C, van Delft FW, Bateman CM, Guo YP, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, Kearney L, Enver T, Greaves M. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469(7330), 356-361.
  • Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ, Moorman AV. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117(7), 2129-2136.
  • Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JAE, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Neira AG, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nature Genetics 2010, 42(6), 492-494.
  • Krishnan S, Wade R, Moorman AV, Mitchell C, Kinsey SE, Eden TOB, Parker C, Vora A, Richards S, Saha V. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia 2010, 24(2), 450-459.
  • Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3), 354-365.
  • Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncology 2010, 11(5), 429-438.
  • Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, Gerrard G, Moorman AV, Duke V, Hoffbrand AV, Fielding AK, Goldstone AH, Foroni L. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology 2010, 148(1), 80-89.
  • Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Revesz T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010, 376(9757), 2009-2017.
  • Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DKH, Wheatley K, de Graaf SSN, van den Berg E, Burnett AK, Gibson BES. Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. Journal of Clinical Oncology 2010, 28(16), 2674-2681.
  • Rai L, Casanova A, Moorman AV, Richards S, Buck G, Goldstone AH, Fielding AK, Foroni L. Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups - a UKALLXII study. British Journal of Haematology 2010, 148(3), 394-401.
  • Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010, 115(2), 206-214.
  • Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009, 114(25), 5136-5145.
  • Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan AK, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009, 113(19), 4489-4496.
  • Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DWA, Prentice AG, Moorman AV, Burnett AK. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology 2009, 145(5), 598-605.
  • Paulsson K, An Q, Moorman AV, Parker H, Molloy G, Davies T, Griffiths MJ, Ross FM, Irving JAE, Harrison CJ, Young BD, Strefford JC. Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukaemia. British Journal of Haematology 2009, 144(6), 838-847.
  • Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 2009, 23(1), 125-133.
  • An Q, Wright SL, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Harrison CJ, Strefford JC. Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. Haematologica 2009, 94(8), 1164-1169.
  • Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving JAE, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab CJ, Tonnies H, Dyer MJ, Siebert R, Harrison CJ. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114(13), 2688-2698.
  • Sulong S, Moorman AV, Irving JAE, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, Parker H, Wright SL, Stewart ARM, Bailey S, Bown NP, Hall AG, Harrison CJ. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 2009, 113(1), 100-107.
  • An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, Strefford JC. Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer. Proceedings of the National Academy of Sciences 2008, 105(44), 17050-17054.
  • Parker H, An Q, Barber K, Case MC, Davies TL, Konn Z, Stewart A, Wright S, Griffiths M, Ross FM, Moorman AV, Hall AG, Irving JAE, Harrison CJ, Strefford JC. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes, Chromosomes and Cancer 2008, 47(12), 1118-1125.
  • Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Karran EL, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJS, Harrison C. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111(1), 387-391.
  • James R, Lightfoot T, Simpson J, Moorman AV, Roman E, Kinsey S. Acute leukemia in children with Down's syndrome: the importance of population based study. Haematologica 2008, 93(8), 1262-1263.
  • Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M. Sequential influences of leukaemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukaemia 14 and 15 trials. Clinical Cancer Research 2007, 13(23), 7059-7066.
  • Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BES, Kinsey SE, Eden TOB, Vora AJ, Mitchell CD, Harrison CJ. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007, 109(6), 2327-2330.
  • Barber KE, Harrison CJ, Broadfield ZJ, Stewart ARM, Wright SL, Martineau M, Moorman AV. Molecular cytogenetic characterisation of TCF3 (E2A)/19p13 rearrangements in acute lymphoblastic leukaemia. Genes, Chromosomes and Cancer 2007, 46(5), 478-486.
  • Moorman AV, Harrison CJ, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood 2007, 109(8), 3189-3197.
  • Robinson HM, Harrison CJ, Moorman AV, Chudoba I, Strefford JC. Intrachromosomal amplification of chromosome 21 (iAMP21) arises from a breakage-fusion-bridge cycle. Genes, Chromosomes and Cancer 2007, 46(4), 318-326.
  • Strefford JC, Worley H, Barber K, Wright S, Stewart ARM, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene 2007, 26(29), 4306-4318.
  • Sanderson, R. N., Johnson, P. R. E., Moorman, A. V., Roman, E., Willett, E., Taylor, P. R., Proctor, S. J., Bown, N., Ogston, S., Bowen, D. T. Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia. Leukemia 2006, 20(3), 444-450.
  • Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ, Langabeer SE, Kottaridis PD, Moorman AV, Burnett A, Linch DC. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005, 106(6), 2113-2119.
  • Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V. Outcome after first relapse in childhood acute lymphoblastic leukaemia: lessons from the United Kingdom R2 trial. British Journal of Haematology 2005, 130(1), 67-75.
  • Moorman AV, Raimondi SC, Pui C-H, Baruchel A, Biondi A, Carroll AJ, Forestier E, Gaynon PS, Harbott J, Harms DO, Heerema N, Pieters R, Schrappe M, Silverman LB, Vilmer E, Harrison CJ. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia 2005, 19(4), 557-563.
  • Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Robinson HM, Strefford JC, Stewart A, Wright S, Griffiths M, Ross FM, Harewood L, Martineau M. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. British Journal of Haematology 2005, 129(4), 520-530.
  • Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, Mitchell C, Vora A, Eden T, Lilleyman JS, Hann I, Saha V. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology 2005, 129(1), 35-44.
  • Robinson HM, Martineau M, Harris RL, Barber KE, Jalali GR, Moorman AV, Strefford JC, Broadfield ZJ, Cheung KL, Harrison CJ. Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia. Leukemia 2005, 19(4), 564-571.
  • Fisher AM, Strike P, Scott C, Moorman AV. Breakpoints of variant 9;22 translocations in chronic myeloid leukemia location preferentially in the CG-richest regions of the genome. Genes, Chromosomes and Cancer 2005, 43(4), 383-389.
  • Martineau M, Jalali GR, Barber KE, Broadfield ZJ, Cheung KL, Lilleyman J, Moorman AV, Richards S, Robinson HM, Ross F, Harrison CJ. ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications. Genes, Chromosomes and Cancer 2005, 43(1), 54-71.
  • Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Robinson HM, Barber KE, Richards SM, Mitchell CD, Eden TO, Hann IM, Hill FG, Kinsey SE, Gibson BES, Lilleyman J, Vora A, Goldstone AH, Franklin IM, Durrant J, Martineau M. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. British Journal of Haematology 2004, 125(5), 552-559.
  • Robinson HM, Taylor KE, Jalali GR, Cheung KL, Harrison CJ, Moorman AV. t(14;19)(q32;q13): a recurrent translocation in B-cell precursor acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 2004, 39(1), 88-92.
  • Barber KE, Ford AM, Harris RL, Harrison CJ, Moorman AV. MLL translocations with concurrent 3' deletions: interpretation of FISH results. Genes, Chromosomes and Cancer 2004, 41(3), 266-271.
  • Harris RL, Harrison CJ, Martineau M, Taylor KE, Moorman AV. Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia?. Cancer Genetics and Cytogenetics 2004, 148(2), 159-162.
  • Gruszka-Westwood AM, Horsley SW, Martinez-Ramirez A, Harrison CJ, Kempski H, Moorman AV, Ross FM, Griffiths M, Greaves MF, Kearney L. Comparative expressed sequence hybridization studies of high-hyperdiploid childhood acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 2004, 41(3), 191-202.
  • Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC, Rutherford S, Allen TD, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Moorman AV, Robinson HM, Harrison CJ. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004, 18(6), 1153-1156.
  • Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, Broadfield ZJ, Harris RL, Taylor KE, Gibson BES, Hann IM, Hill FGH, Kinsey SE, Eden TOB, Mitchell CD, Harrison CJ. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003, 102(8), 2756-2762.
  • Moorman AV, Martineau M, Harrison CJ. Frequency of ETV6/AML1 fusion in adult acute lymphoblastic leukaemia - response to Cuneo et al. Leukemia 2003, 17(2), 477-477.
  • Harewood L, Robinson H, Harris R, Al-Obaidi MJ, Jalali GR, Martineau M, Moorman AV, Sumption N, Richards S, Mitchell C, Harrison CJ. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003, 17(3), 547-553.
  • Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR, Martineau M, Moorman AV, Taylor KE, Richards S, Mitchell C, Harrison CJ. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 2003, 17(11), 2249-2250.
  • Moorman AV, Roman E, Cartwright RA, Morgan GJ. Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. British Journal of Cancer 2002, 86(1), 60-62.
  • Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. British Journal of Haematology 2002, 118(4), 1071-1077.
  • Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright PA, Morgan GJ, Wild CP. Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. British Journal of Haematology 2002, 116(3), 587-594.
  • Moorman AV, Roman E, Cartwright RA, Morgan GJ. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia. British Journal of Cancer 2002, 86(7), 1061-1063.
  • Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, Roman E, Cartwright RA, Morgan GJ. Polymorphism in glutathione S-transferase PI is associated with susceptibility to chemotherapy-induced leukaemia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(20), 11592-11597.
  • Moorman AV, Roman E, Kane EV, Dovey GJ, Cartwright RA, Morgan GJ. Karyotype and age in acute myeloid leukaemia: are they linked?. Cancer Genetics and Cytogenetics 2001, 126(2), 155-161.
  • Feltbower RG, Moorman AV, Dovey G, Kinsey SE, McKinney PA. Incidence of childhood acute lymphoblastic leukaemia in Yorkshire, UK. Lancet 2001, 358(9279), 385-387.
  • Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, Gibson B, Richards S. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology 2001, 113(1), 103-114.
  • Greaves MF, Eden OB, Harrison CJ, Moorman AV, Roman E, Simpson J, Craft A, Hale J, Kernahan J, Reid M, Windebank K, Pearson A, Skinner R, As part of the United Kingdom Childhood Cancer Study Group. The United Kingdom Childhood Cancer Study: objectives, materials and methods. British Journal of Cancer 2000, 82(5), 1073-1102.
  • Clark R, Byatt S-A, Bennett CF, Brama M, Martineau M, Moorman AV, Roberts K, Secker-Walker LM, Richards S, Eden OB, Goldstone AH, Harrison CJ. Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukaemia. Leukemia 2000, 14(2), 241-246.
  • Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-Walker LM. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. Leukemia 1998, 12(5), 805-810.
  • Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. Leukemia 1998, 12(5), 788-791.
  • Lillington DM, Young BD, Martineau M, Berger R, Moorman AV, Secker-Walker LM. The t(10;11)(p12;q23) translocation in acute leukemia: a cytogenetic and clinical profile of 20 patients. Leukemia 1998, 12(5), 801-804.
  • Harrison CJ, Cuneo A, Clark R, Johansson B, Lafage-Pochitaloff M, Moorman AV, Secker-Walker LM. Ten novel 11q23 chromosomal partner sites. Leukemia 1998, 12(5), 811-822.
  • Secker-Walker LM, Moorman AV, Bain BJ, Mehta AB. Secondary acute leukaemia and myelodysplastic syndrome with 11q23 abnormalities. Leukemia 1998, 12(5), 840-844.
  • Bain BJ, Moorman AV, Johansson B, Mehta AB, Secker-Walker LM. Myelodysplastic syndromes associated with 11q23 abnormalities. Leukemia 1998, 12(5), 834-839.
  • Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23) - a laboratory and clinical study of 125 cases. Leukemia 1998, 12(5), 792-800.
  • Harbott J, Mancini M, Verellen-Dumoulin C, Moorman AV, Secker-Walker LM. Hematological malignancies with a deletion of 11q23: cytogenetic and clinical aspects. Leukemia 1998, 12(5), 823-827.
  • Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic, and clinical study of 183 cases. Leukemia 1998, 12(5), 779-787.
  • Johansson B, Moorman AV, Secker-Walker LM. Derivative chromosomes of 11q23-translocations in hematologic malignancies. Leukemia 1998, 12(5), 828-833.
  • Moorman AV, Clark R, Farrell DM, Hawkins JM, Martineau M, Secker-Walker LM. Probes for hidden hyperdiploidy in acute lymphoblastic leukaemia. Genes, Chromosomes and Cancer 1996, 16(1), 40-45.
  • Martineau M, Clark R, Farrell DM, Hawkins JM, Moorman AV, Secker-Walker LM. Isochromosomes in acute lymphoblastic leukaemia: i(21q) is a significant finding. Genes, Chromosomes and Cancer 1996, 17(1), 21-30.
  • Hawkins JM, Bain BJ, Mehta AB, Moorman AV. Complex hyperdiploidy in acute myeloid leukaemia: a United Kingdom Cancer Cytogenetics Group Study. Leukemia Research 1995, 19(12), 905-913.
  • Hawkins JM, Moorman AV, Hoffbrand AV, Martineau M, Wright FS, Mehta AB, Prentice HG, Secker-Walker LM. Association of 17p loss with late-stage or refractory disease in hematologic malignancy. Cancer Genetics and Cytogenetics 1994, 77(2), 134-143.

• Book Chapter

  • Andersson A, Moorman AV, Harrison CJ, Mullighan C. Acute lymphoblastic leukaemia. In: Tosi S; Reid AG, ed. The Genetic Basis of Haematological Cancers. Chichester: Wiley Blackwell, 2016, pp.223-264.

• Conference Proceedings (inc. Abstracts)

  • Creasey T, Enshaei A, Watts K, Cuthbert G, Schwab C, Harrison CJ, Vora A, Fielding AK, Moorman AV. Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. In: 61st ASH Annual Meeting. 2019, Orlando, FL, USA: American Society of Hematology.
  • Michels N, Boer JM, Lopez-Yurda M, De Groot-Kruseman HA, van der Velden V, Moorman AV, Enshaei A, Vora A, Sutton R, Trahair T, Dalla-Pozza L, Pieters R, Zwaan MC, Den Boer ML. Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study. In: 61st ASH Annual Meeting. 2019, Orlando, FL, USA: ASH Publications.
  • Moorman A, Kirkwood A, Enshaei A, Clifton-Hadley L, Lawrie E, Marks D, McMillan A, Menne A, Patrick P, Wrench B, Zuborne-Alapi K, Rowntree C, Fielding A. Clinical Efficacy of a Novel Validated Prognostic Index for Trial Design in Adult Acute Lymphoblastic Leukaemia. In: 24th Congress of the European Hematology Association. 2019, Amsterdam: Lippincott, Williams & Wilkins.
  • Zhou P, Enshaei A, Newman AM, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphona in Malawi. In: Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP). 2018, Kyoto, Japan: Pediatric Blood and Cancer.
  • Zhou P, Enshaei A, Newman AM, Banda K, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakjang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A genomic classification model enables risk stratification of paediatric endemic Burkitt lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Schwab C, Enshaei A, Roberts KG, Russell LJ, Harvey RC, Chen IM, Willman CL, Mullighan C, Vora AJ, Moorman AV, Harrison CH. The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003. In: American Society of Hematology (ASH). 2016, San Diego, CA, USA: American Society of Hematology.
  • Moorman AV, Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CH, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL). In: 58th American Society of Hematology (ASH) Annual Meeting. 2016, San Diego, CA, USA: American Society of Hematology.
  • Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Samarasinghe S, Linch DC, Moorman A, Goulden N, Vora A, Mansour MR. Early immature T-ALL as determined by absence of bi-allelic deletion at the TCR gamma locus is not an adverse prognostic factor on the MRC UKALL2003 trial. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Fondazione Ferrata Storti.
  • Furness CL, Rowntree C, Vora AJ, Kirkwood AA, Mitchell C, Goulden N, Moorman AV, Hough R. Use of Morphological Early Response Data to Predict Relapse in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL). In: 57th ASH Annual Meeting and Exposition. 2015, Orlando, Florida: American Society of Hematology.
  • Enshaei A, Schwab C, Chilton L, Wade R, Hancock J, Mitchell C, Kinsey SE, Goulden N, Vora AJ, Harrison C, Moorman AV. Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
  • Enshaei A, Schwab C, Chilton L, Wade R, Hancock J, Mitchell C, Kinsey SE, Goulden N, Vora AJ, Harrison C, Moorman AV. Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Sellar RS, Rowntree C, Vora AJ, Furness CL, Goulden N, Mitchell C, Moorman AV, Hough R. Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Chilton L, Harrison C, Moorman AV, Ashworth I, Burnett AK, Grimwade D, Hills RK. Prognostic Significance and Risk Stratification in Acute Myeloid Leukaemia Patients in the Absence of Successful Cytogenetic Analysis. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:A Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD: Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • O'Connor D, Bartram J, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • Roberts KG, Payne-Turner D, McCastlain K, Gu ZH, Iacobucci I, Harvey RC, Chen IM, Valentine M, Pei D, Li Y, Zhang J, Cheng C, Rambaldi A, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger S, Kohlschmidt J, Mrozek K, Marcucci G, Bioomfield CD, Stock W, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG. High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Bourquin JP, Fischer U, Forster M, Rinaldil A, Risch T, Sungalee S, Hans-Jorg W, Bornhauser B, Michael G, Christina K, Adrian S, Marc S, Catherine W, Amstislavskiy V, Baruchel A, Thies B, Giuseppe B, Gunnar C, Helene C, Dardanel D, Mauro D, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas O, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Holl J, Homhardt S, Husemann P, te Kronnie G, Lehrach H, Marovca B, Niggli F, McHardy A, Moorman A, Panzer-Grumayer R, Petersen BS, Raeder B, Ralser M, Rosenstiel P, Schafer D, Schrappe M, Schreiber S, Schutte M, Stade B, Tchindal J, Thiele R, Vora A, Zaliova M, Zichner T, Zimmermann M, Borkhardt A, Franke A, Korbel JO, Stanulla M, Yaspo ML. Genomic and Drug Response Profiling of Fatal TCF3-HLF-Positive Pediatric Acute Lymphoblastic Leukaemia Identifies Recurrent Mutation Patterns and Novel Therapeutic Options. In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Fondazione Ferrata Storti.
  • Moorman AV, Irving J, Enshaei A, Parker CA, Sutton R, Kuiper R, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V. Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna: Ferrata Storti Foundation.
  • Russell LR, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • Russell LJ, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
  • Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, Heatley SL, Loh ML, Konopleva M, Chen IM, Zimmermannova O, Schwab C, Smith O, Mozziconacci MJ, Chabannon C, Kim M, Falkenburg JHF, Norton A, Marshall K, Haas OA, Starkova J, Stuchly J, Hunger SP, White D, Mullighan CG, Willman CL, Stary J, Trka J, Zuna J. Characterization of Leukemias with ETV6-ABL1 Fusion. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
  • Gabriel AS, Enshaei A, Taylor J, Erhorn A, Schwab C, Rai L, Fielding A, Goulden N, Vora A, Harrison CJ, Moorman AV. Age specific incidence of partner gene and secondary abnormalities in MLL positive acute lymphoblastic leukaemia (ALL). In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata-Storti Foundation/European Hematology Association.
  • Hrusak O, Luks A, Janotova I, Mejstrikova E, Vaskova M, Bleckmann K, Konatkowska B, Irving J, Polgarova K, Inaba H, Schmiegelow K, Rossi JG, Felice MS, Dalla-Pozza L, Morales J, Sartor M, Dworzak M, Moricke A, Campbell M, Cabrera ME, Marinov N, Elitzur S, Izraeli S, De Haas V, Kolenova A, Svec P, Kreminska E, Stokley S, Polychronopoulou S, da Costa E, Marquart HV, Kattamis A, Ratel R, Reinhardt D, Jackson K, Moorman AV, Schrappe M, Stary J. Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. In: 57th ASH Annual Meeting and Exposition. 2015, Orlando, USA: American Society of Hematology.
  • Zakout G, Rai L, Moorman AV, Fielding AK. TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco: American Society of Hematology.
  • Zakout G, Rai-Shetty L, Moorman AV, Fielding AK. Telomere DNA content and TP53 state provide an insight into genomic instability in older adult patients with all. In: 19th Congress of the European-Hematology-Association. 2014, Milan, ITALY: Ferrata Storti Foundation.
  • Schwab C, Andrews R, Chilton L, Elliott A, Richardson S, Ryan SL, Logan A, Fielding AK, Goulden N, Vora AJ, Moorman AV, Macartney CA, Harrison CJ. SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge PM, Horstmann MA, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, Pombo-de-Oliveira MD, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn NC, Sutton R, Schwab C, Enshaei A, Vora AJ, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmerman M, Moorman AV, Pieters R, Den Boer ML. Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Zimmermannova O, Zaliova M, Moorman AV, Fronkova E, Stary J, Trka J, Kalina T, Zuna J. Potential Involvement of Physiological TCR Gamma Delta Clones in Immune Surveillance of Preleukemic Cells. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Jenkinson S, Kirkwood AA, Goulden N, Vora AJ, Mitchell C, Wade R, Hancock J, Moorman AV, Linch DC, Gale RE. No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Lafta F, Rand V, Moorman A, Mitchell C, Kinsey S, Vora A, Cockell S, Schwalbel E, Enshaei A, Strathdee G. Investigation of methylation based biomarkers for prediction of relapse in good prognostic cytogenetic subgroups of childhood acute lymphoblastic leukaemia. In: 10th NCRI Cancer Conference. 2014, Liverpool, UK.
  • Schwab C, Andrews R, Chilton L, Elliott A, Keil G, Richardson S, Ryan SL, Wragg C, Moppett J, Cummins M, Goulden N, Vora AJ, Moorman AV, Harrison CJ. EBF1-PDGFRB Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Li Y, Schwab C, Ryan S, Papaemmanuil E, Robinson HM, Jacobs P, Van Loo P, Stratton MR, Campbell PJ, Harrison CJ. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. In: 23rd Biennial Congress of the European Association for Cancer Research. 2014, Munich, Germany: Pergamon Press.
  • Beaton B, Patel B, Dey A, Castleton A, Moorman A, McMillan A, Rowntree C, Marks D, Menne T, Micklewright L, Smith P, Purnell S, Fielding AK. CD20 Expression in Adults with Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) from UKALL14, its Regulation by Dexamethasone and Rituximab Induced Cytotoxicity. In: 19th Congress of the European Hematology Association. 2014, Milan, Italy: Fondazione Ferrata Storti.
  • Boer J, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, HA de Groot-Kruseman, Kuiper RP, Hoogerbrugge PM, Horstmann MA, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn NC, Sutton R, Schwab C, Enshaei A, Vora AJ, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmerman M, Moorman AV, Pieters R, Den Boer ML. 368 Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, USA: American Society of Hematology.
  • Moorman AV, Enshaei A, Schwab C, Chilton L, Wade R, Goulden N, Vora AJ, Harrison CJ. Integration Of Cytogenetic and Copy Number Alteration (CNA) Data Into a Single Risk Profile For Paediatric Acute Lymphoblastic Leukaemia (ALL). In: 55th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2013, New Orleans, Louisiana: American Society of Hematology.
  • Jenkinson S, Koo K, Goulden N, Vora A, Mitchell C, Wade R, Richards SM, Hancock J, Moorman AV, Linch DC, Gale RE. Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial. In: BRITISH JOURNAL OF HAEMATOLOGY. 2012, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA: WILEY-BLACKWELL.
  • Harrison CJ, Moorman AV, Schwab C, Heerema NA, Carroll AJ, Haas OA. Intrachromosomal Amplification of Chromosome 21(iAMP21): Cytogenetic Characterisation and Outcome in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). A Study On Behalf of the Ponte Di Legno International Childhood ALL Workshop. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Rabin KR, Mason CC, Gurusiddappa S, Leung HCE, Morrison DJ, Bhojwani D, Barnette P, South ST, Miles RR, Devidas M, Pession A, Basso G, Potter NE, Kearney L, Moorman AV, Raimondi SC, Jeha S, Pui CH, Carroll WL, Loh ML, Hunger SP, Mullighan CG, Schiffman JD. IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Schwab C, Chilton L, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Moorman AV, Harrison CJ. Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL) Are Associated with Major Cytogenetic Subgroups. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Moorman AV, Enshaie A, Chilton L, Schwab C, Tembo T, Richards S, Kinsey S, Vora AJ, Mitchell C, Harrison CJ. Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Schwab C, Chilton L, Enshaie A, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Vora AJ, Mitchell CD, Richards SM, Goulden N, Kinsey S, Moorman AV, Harrison CJ. Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL). In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Allen CG, Hills RK, Evans CM, Lamb K, Sellar R, Moorman AV, Sale M, Liu-Yin JA, Burnett AK, Linch DC, Gale RE. Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
  • Fong CYK, Parker CA, Hussain A, Liu JZ, Essink M, Kuehnel HJ, Lancaster DL, Pridham G, Payne D, O'Horo C, Krishnan S, Hancock J, Goulden N, Moorman AV, Richards S, Vora AJ, Saha V, Masurekar AN. Intramuscular PEG-Asparaginase At 1000 U/m(2) Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
  • Buitenkamp T, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel MM, Pieters R, de Haas V, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Cazzaniga G, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Mondelaers V, Lammens T, Cave H, Stark B, Moorman AV, Vora AJ, Hunger S, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk J, Whitlock JA, Zwaan CM. Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group. In: Blood: 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH). 2011, San Diego, California, USA: American Society of Hematology.
  • Bailey S, Skinner R, Carey P, Moorman A, Banda K, Banda F, Eden OB, Israels T, Molyneux E. Acute lymphoblastic leukarmia (ALL) in Malawi, progress in the first Malawi ALL protocol. In: Pediatric Blood & Cancer: 43rd Congress of the International Society of Paediatric Oncology (SIOP). 2011, Auckland, New Zealand: John Wiley & Sons, Inc.
  • Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. In: 50th Annual Scientific Meeting of the British Society for Haematology. 2010, Edinburgh, Scotland: British Journal of Haematology, Wiley-Blackwell Publishing.
  • Lrrzow MR, Buck G, Dewald G, Fielding A, Ketterling R, Lazarus HM, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Masurekar AN, Parker CA, Choudhuri S, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Goulden N, Green N, Revesz T, Hoogerbrugge P, Darbyshire P, Love S, Saha V. Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Fielding AK, Buck G, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Tallman MS, Rowe JM, Goldstone AH. Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology Annual Meeting. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Fielding AK, Buck G, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Paietta E, Richards SM, Tallman MS, Rowe JM, Goldstone AH. Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Rand V, Parker H, Russell LJ, Irving J, Jones L, Masic D, Minto L, Morrison H, Robinson H, Schwab C, Sinclair P, Moorman AV, Strefford JC, Harrison CJ. What Is the Initiating Mechanism of iAMP21 in Childhood B Cell Precursor ALL?. In: Blood: 51st Annual Meeting of the American Society of Hematology. 2009, New Orleans, LA: American Society of Hematology.
  • Grimwade J, Hills R, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in AML: Determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5635 younger adults treated in the UK MRC Trails. In: Abstracts of the 14th Congress of the European Hematology Association. 2009, Berlin, Germany: Haematologica: Fondazione Ferrata Storti.
  • Moorman AV, Ensor HM, Chilton L, Richards SM, Kinsey SE, Vora AJ, Mitchell CD, Harrison CJ. Prognostic Relevance of Cytogenetics in Childhood Acute Lymphoblastic Leukaemia (ALL): Final Results From MRC ALL97. In: 51st Annual Meeting of the American Society of Hematology. 2009, New Orleans, LA: Blood: American Society of Hematology.
  • Moorman AV, Konn ZJ, Barber KE, Wright SL, Stewart ARM, Parker H, Richards SM, Kinsey SE, Eden OB, Vora AJ, Mitchell CD, Strefford JC, Harrison CJ. The Spectrum and Prognostic Relevance of Additional Abnormalities, Involving 12p and 21q, in Children with ETV6-RUNX1 Positive Acute Lymphoblastic Leukaemia (ALL). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
  • Rowe JM, Buck G, Moorman AV, Tallman MS, Richards SM, Fielding AK, Burnett AK, Franklin IM, Wiernik PH, Lazarus HM, Paietta E, Litzow MR, Marks DI, Luger S, Dewald GW, Goldstone AH. Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
  • Moorman AV, Sulong S, Irving JAE, Strefford JC, Case MC, Minto CLJ, Harrison CJ, Hall AG. Inactivation of CDKN2A in childhood acute lymphoblastic leukaemia (ALL) occurs principally by deletion and is strongly correlated with cytogenetic subgroups. In: British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
  • Russell LJ, Capasso M, Vater I, Moorman AV, Akasaka T, Harder L, Heidenreich O, Machado L, Gest S, Strefford JC, Chandrasekaran T, Tonnies H, Majid A, Bernard O, Dyer MJS, Siebert R, Harrison CJ. IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
  • Strefford JC, An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Parker H, Moorman AV, Hall A, Irving J, Harrison CJ. Heterogeneous breakpoints target PAX5 in acute lymphoblastic leukaemia patients with dicentric chromosomes. In: Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: British Journal of Haematology: Wiley-Blackwell Publishing Ltd.
  • Moorman AV, Richards SM, Hancock JP, Mitchell CD, Vora AJ, Harrison CJ, Goulden NJ. Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL). In: 48th Annual Scientific Meeting of the British Society of Haematology, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow: British Journal of Haematology: Wiley-Blackwell.
  • Strefford JC, An Q, Wright SL, Konn ZJ, Matherson E, Minto L, Moorman AV, Parker H, Hall A, Irving J, Harrison CJ. Variable Breakpoints Target PAX5 in Patients with Dicentric Chromosomes: A Model for the Basis of Unbalanced Translocations in Cancer. In: 49th Annual Meeting of the American Society of Hematology. 2007, Atlanta, Georgia: Blood: American Society of Hematology.
  • Moorman AV, Sulong S, Irving JAE, Strefford JC, Case MC, Minto L, Harrison CJ, Hall AG. Red blood cell alloimmunization is affected by depletion of donor white cell subsets. In: 49th Annual Meeting of the American Society of Hematology. 2007, Atlanta, Georgia: Blood: American Society of Hematology.
  • Strefford J, Worley H, Barber KJ, Wright SL, Moorman AV, Case M, Irving J, Hall A, Harrison CJ. Genomic profiling reveals multiple genetic targets in ETV6-RUNX1 positive acute lymphoblastic leukaemia (ALL). In: British Human Genetics Conference. 2007, University of York, UK: Journal of Medical Genetics: BMJ Group.
  • Broadfield Z, Martineau M, Moorman AV, Wright SL, Bown N, Harrison CJ. PAX5-ETV6 fusion in acute lymphoblastic leukaemia des not define the dic(9;12). In: JOURNAL OF MEDICAL GENETICS. 2006.
  • Sanderson RN, Johnson PRE, Maguire C, Moorman AV, Roman E, Willett E, Bown NP, Taylor P, Proctor SJ, Bowen DT. Population-based study of unselected acute myeloid leukemia cases reveals distinct cytogenetic pathways analogous to therapy-related AML/MDS. In: Abstracts of the 45th Annual Meeting of the American Society of Hematology. 2003, San Diego, California: Blood: American Society of Hematology.

• Editorials

  • Moorman AV. Does TP53 guard ALL genomes?. Blood 2014, 124(2), 160-161.
  • Moorman AV. One man's dose, another man's poison. Blood 2008, 111(7), 3303-3304.

• Letters

  • Connor DO, Joy M, Enshaei A, Kirkwood A, Kearns PR, Samarasinghe S, Moppett J, Moorman AV, Vora A. Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL. Blood Advances 2023, 7(23), 7231-7234.
  • Gallon R, Phelps R, Betts L, Hayes C, Masic D, Irving JAE, McAnulty C, Saha V, Vora A, Wimmer K, Motwani J, Macartney C, Burn J, Jackson MS, Moorman AV, Santibanez-Koref M. Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia. Leukemia and Lymphoma 2023, 64(1), 217-220.
  • Schwab C, Roberts K, Boer JM, Gohring G, Steinemann D, Vora A, Macartney C, Hough R, Thorn Z, Dillon R, Escherich G, Cazzaniga G, Schlegelberger B, Loh M, den Boer ML, Moorman AV, Harrison CJ. SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood 2021, 137(13), 1835-1838.
  • Chagaluka G, Schwalbe EC, Chakumatha E, Carey P, O'Brien S, Moorman A, Barretta E, Rogers ES, Dunsmure A, Israels T, Molyneux EM, Bailey S. Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting — the Blantyre experience. British Journal of Haematology 2020, 191(3), e87-e90.
  • Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Hancock J, Samarasinghe S, Linch DC, Moorman AV, Goulden N, Vora A, Mansour MR. Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial. Haematologica 2018, 103(7), e288-e292.
  • Zimmermannova O, Zaliova M, Moorman AV, Al-Shehhi H, Fronkova E, Zemanova Z, Kalina T, Vora A, Stary J, Trka J, Hrusak O, Zuna J. Acute lymphoblastic leukemia with aleukemic prodrome: Preleukemic dynamics and possible mechanisms of immunosurveillance. Haematologica 2017, 102(6), e225-e228.
  • De Lorenzo P, Moorman AV, Pieters R, Dreyer ZE, Heerema NA, Carroll AJ, Hunger SP, Harvey R, Willman CL, Devidas M, Valsecchi MG, Harrison CJ. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia 2014, 28(2), 428-430.
  • O'Reilly J, Russell LJ, Cooney J, Ensor HM, Purtill D, Wright M, Moorman AV. Unravelling the prognostic effect of IKZF1 deletions and IGH@-CRLF2 in adult acute lymphoblastic leukaemia. Pathology 2013, 45(6), 609-612.
  • Chagaluka G, Carey P, Banda K, Schwab C, Chilton L, Schwalbe E, Skinner R, Israels T, Moorman A, Molyneux E, Bailey S. Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica 2013, 98(1), e1-e3.
  • Safavi S, Forestier E, Golovleva I, Barbany G, Nord KH, Moorman AV, Harrison CJ, Johansson B, Paulsson K. Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia. Leukemia 2013, 27(1), 248-250.
  • Paulsson K, Harrison CJ, Andersen MK, Chilton L, Nordgren A, Moorman AV, Johansson B. Distinct patterns of gained chromosomes in high hyperdiploid acute lymphoblastic leukemia with t(1;19)(q23;p13), t(9;22)(q34;q22) or MLL rearrangements. Leukemia 2013, 27(4), 974-977.
  • Buitenkamp TD, Pieters R, Zimmermann M, de Haas V, Richards SM, Vora AJ, Mitchell CD, Schwab C, Harrison CJ, Moorman AV, van den Heuvel-Eibrink MM, Zwaan CM. BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia. Leukemia 2013, 27(1), 251-252.
  • Eyre T, Schwab CJ, Kinstrie R, McGuire AK, Strefford J, Peniket A, Mead A, Littlewood T, Holyoake TL, Copland M, Moorman AV, Harrison CJ, Vyas P. Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012, 120(22), 4441-4443.
  • Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. Age- and sex-adjusted incidence rates of adults with acute lymphoblastic leukemia (ALL) in the northern part of England Response. Blood 2010, 116(6), 1012-1012.
  • Russell LJ, DeCastro DG, Griffiths M, Telford N, Bernard O, Panzer-Gruemayer R, Heidenreich O, Moorman AV, Harrison CJ. A novel translocation, t(14;19)(q32;p13) involving IGHalpha and the cytokine receptor for erythropoietin. Leukemia 2009, 23, 614-617.
  • Moorman AV, Roman E, Cartwright RA, Morgan GJ. Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK. Clinical and Laboratory Haematology 2002, 24(4), 263-265.
  • Moorman AV, Richards S, Harrison CJ. Involvement of the MLL gene in T-lineage acute lymphoblastic leukaemia. Blood 2002, 100(6), 2273-2273.

• Notes

  • Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nothen MM, Heilmann-Heimbach S, Jockel K-H, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Henderson BE, Haiman CA, Benlloch S, Schumacher FR, Olama AAA, Berndt SI, Conti DV, Wiklund F, Chanock S, Stevens VL, Tangen CM, Batra J, Clements J, Gronberg H, Schleutker J, Albanes D, Weinstein S, Wolk A, West C, Mucci L, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Neal DE, Travis RC, Hamilton RJ, Ingles SA, Rosenstein B, Lu Y-J, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS. Author correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nature Communications 2019, 10(1), 419.
  • Moorman AV. Time for ALL adults to catch up with the children. Blood 2017, 130(16), 1781-1783.

• Reviews

  • Moorman AV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 2016, 101(4), 407-416.
  • Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Reviews 2012, 26(3), 123-135.